Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East

Wael Almahmeed; Zainab Alabadla; Fatheya Al Awadi; Dalal Alrohmaihi; Mostafa AlShamiri; Hussein Elbadawi; Hassan El-Tamimi; Abdel Nasser Elzouki; Mohamed Farghaly; Khadija Hafidh; Mohamed Hassanein; Adel Khalifa Hamad; Kamlesh Khunti; Hani Sabbour; Aletta E. Schutte

doi:10.1007/s12325-024-03103-5

Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East

Wael Almahmeed
, Zainab Alabadla
, Fatheya Al Awadi
, Dalal Alrohmaihi
, Mostafa AlShamiri
, Hussein Elbadawi
, Hassan El-Tamimi
, Abdel Nasser Elzouki
, Mohamed Farghaly
, Khadija Hafidh
, Mohamed Hassanein
, Adel Khalifa Hamad
, Kamlesh Khunti
, Hani Sabbour
, Aletta E. Schutte

Al Jalila Children's Specialty Hospital
Dubai Hospital
Awali Hospital
King Saud University
My Clinic International
Mediclinic Parkview Hospital
Hamad Medical Corporation
Dubai Medical College
Mohamed Bin Rashid College of Medicine and Health Sciences
Mohammed Bin Khalifa Cardiac Centre
University of Leicester
Mediclinic Airport Road Hospital
University of New South Wales
The George Institute for Global Health

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Hypertension, dyslipidemia, and type 2 diabetes are highly prevalent and poorly controlled cardiometabolic diseases in the Middle East. Therapeutic non-adherence and therapeutic inertia are major contributors to this suboptimal disease control. Regardless of the cardiometabolic disease, evidence-based solutions may be used to improve therapeutic non-adherence and overcome inertia, and thereby help to alleviate the heavy burden of cardiovascular disease in the Middle East. Such solutions include the routine and early use of single-pill combinations, educational initiatives for patients, and multidisciplinary team-based care. This article highlights these and other potential solutions for therapeutic non-adherence and inertia, as discussed at the 2024 Evidence in the Cardiometabolic Environment (EVIDENT) Summit. There is now a ‘call-to-action’ from healthcare providers and other stakeholder groups to ensure that the solutions discussed at this meeting are implemented within health systems in the Middle East to significantly improve cardiovascular outcomes. Infographic available for this article.

Original language	English
Article number	e102830
Pages (from-to)	1340-1359
Number of pages	20
Journal	Advances in Therapy
Volume	42
Issue number	3
DOIs	https://doi.org/10.1007/s12325-024-03103-5
State	Published - Mar 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Dyslipidemia
Hypertension
Therapeutic adherence
Therapeutic inertia
Type 2 diabetes

Access to Document

10.1007/s12325-024-03103-5

Cite this

Almahmeed, W., Alabadla, Z., Al Awadi, F., Alrohmaihi, D., AlShamiri, M., Elbadawi, H., El-Tamimi, H., Elzouki, A. N., Farghaly, M., Hafidh, K., Hassanein, M., Hamad, A. K., Khunti, K., Sabbour, H., & Schutte, A. E. (2025). Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East. Advances in Therapy, 42(3), 1340-1359. Article e102830. https://doi.org/10.1007/s12325-024-03103-5

@article{5dbb25f59a4148b392811cda8e74974f,

title = "Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East",

abstract = "Hypertension, dyslipidemia, and type 2 diabetes are highly prevalent and poorly controlled cardiometabolic diseases in the Middle East. Therapeutic non-adherence and therapeutic inertia are major contributors to this suboptimal disease control. Regardless of the cardiometabolic disease, evidence-based solutions may be used to improve therapeutic non-adherence and overcome inertia, and thereby help to alleviate the heavy burden of cardiovascular disease in the Middle East. Such solutions include the routine and early use of single-pill combinations, educational initiatives for patients, and multidisciplinary team-based care. This article highlights these and other potential solutions for therapeutic non-adherence and inertia, as discussed at the 2024 Evidence in the Cardiometabolic Environment (EVIDENT) Summit. There is now a {\textquoteleft}call-to-action{\textquoteright} from healthcare providers and other stakeholder groups to ensure that the solutions discussed at this meeting are implemented within health systems in the Middle East to significantly improve cardiovascular outcomes. Infographic available for this article.",

keywords = "Dyslipidemia, Hypertension, Therapeutic adherence, Therapeutic inertia, Type 2 diabetes",

author = "Wael Almahmeed and Zainab Alabadla and \{Al Awadi\}, Fatheya and Dalal Alrohmaihi and Mostafa AlShamiri and Hussein Elbadawi and Hassan El-Tamimi and Elzouki, \{Abdel Nasser\} and Mohamed Farghaly and Khadija Hafidh and Mohamed Hassanein and Hamad, \{Adel Khalifa\} and Kamlesh Khunti and Hani Sabbour and Schutte, \{Aletta E.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = mar,

doi = "10.1007/s12325-024-03103-5",

language = "English",

volume = "42",

pages = "1340--1359",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Adis",

number = "3",

}

Almahmeed, W, Alabadla, Z, Al Awadi, F, Alrohmaihi, D, AlShamiri, M, Elbadawi, H, El-Tamimi, H, Elzouki, AN, Farghaly, M , Hafidh, K , Hassanein, M, Hamad, AK, Khunti, K, Sabbour, H & Schutte, AE 2025, 'Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East', Advances in Therapy, vol. 42, no. 3, e102830, pp. 1340-1359. https://doi.org/10.1007/s12325-024-03103-5

Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East. / Almahmeed, Wael; Alabadla, Zainab; Al Awadi, Fatheya et al.
In: Advances in Therapy, Vol. 42, No. 3, e102830, 03.2025, p. 1340-1359.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases

T2 - A Call-to-Action from the Middle East

AU - Almahmeed, Wael

AU - Alabadla, Zainab

AU - Al Awadi, Fatheya

AU - Alrohmaihi, Dalal

AU - AlShamiri, Mostafa

AU - Elbadawi, Hussein

AU - El-Tamimi, Hassan

AU - Elzouki, Abdel Nasser

AU - Farghaly, Mohamed

AU - Hafidh, Khadija

AU - Hassanein, Mohamed

AU - Hamad, Adel Khalifa

AU - Khunti, Kamlesh

AU - Sabbour, Hani

AU - Schutte, Aletta E.

PY - 2025/3

Y1 - 2025/3

N2 - Hypertension, dyslipidemia, and type 2 diabetes are highly prevalent and poorly controlled cardiometabolic diseases in the Middle East. Therapeutic non-adherence and therapeutic inertia are major contributors to this suboptimal disease control. Regardless of the cardiometabolic disease, evidence-based solutions may be used to improve therapeutic non-adherence and overcome inertia, and thereby help to alleviate the heavy burden of cardiovascular disease in the Middle East. Such solutions include the routine and early use of single-pill combinations, educational initiatives for patients, and multidisciplinary team-based care. This article highlights these and other potential solutions for therapeutic non-adherence and inertia, as discussed at the 2024 Evidence in the Cardiometabolic Environment (EVIDENT) Summit. There is now a ‘call-to-action’ from healthcare providers and other stakeholder groups to ensure that the solutions discussed at this meeting are implemented within health systems in the Middle East to significantly improve cardiovascular outcomes. Infographic available for this article.

AB - Hypertension, dyslipidemia, and type 2 diabetes are highly prevalent and poorly controlled cardiometabolic diseases in the Middle East. Therapeutic non-adherence and therapeutic inertia are major contributors to this suboptimal disease control. Regardless of the cardiometabolic disease, evidence-based solutions may be used to improve therapeutic non-adherence and overcome inertia, and thereby help to alleviate the heavy burden of cardiovascular disease in the Middle East. Such solutions include the routine and early use of single-pill combinations, educational initiatives for patients, and multidisciplinary team-based care. This article highlights these and other potential solutions for therapeutic non-adherence and inertia, as discussed at the 2024 Evidence in the Cardiometabolic Environment (EVIDENT) Summit. There is now a ‘call-to-action’ from healthcare providers and other stakeholder groups to ensure that the solutions discussed at this meeting are implemented within health systems in the Middle East to significantly improve cardiovascular outcomes. Infographic available for this article.

KW - Dyslipidemia

KW - Hypertension

KW - Therapeutic adherence

KW - Therapeutic inertia

KW - Type 2 diabetes

UR - https://www.scopus.com/pages/publications/85217203698

U2 - 10.1007/s12325-024-03103-5

DO - 10.1007/s12325-024-03103-5

M3 - Review article

C2 - 39841371

AN - SCOPUS:85217203698

SN - 0741-238X

VL - 42

SP - 1340

EP - 1359

JO - Advances in Therapy

JF - Advances in Therapy

IS - 3

M1 - e102830

ER -

Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this